204 related articles for article (PubMed ID: 25143071)
1. ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
Pandit-Taskar N; O'Donoghue JA; Beylergil V; Lyashchenko S; Ruan S; Solomon SB; Durack JC; Carrasquillo JA; Lefkowitz RA; Gonen M; Lewis JS; Holland JP; Cheal SM; Reuter VE; Osborne JR; Loda MF; Smith-Jones PM; Weber WA; Bander NH; Scher HI; Morris MJ; Larson SM
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2093-105. PubMed ID: 25143071
[TBL] [Abstract][Full Text] [Related]
2. Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using
Carrasquillo JA; Fine BM; Pandit-Taskar N; Larson SM; Fleming SE; Fox JJ; Cheal SM; O'Donoghue JA; Ruan S; Ragupathi G; Lyashchenko SK; Humm JL; Scher HI; Gönen M; Williams SP; Danila DC; Morris MJ
J Nucl Med; 2019 Nov; 60(11):1517-1523. PubMed ID: 31053681
[TBL] [Abstract][Full Text] [Related]
3. Optimization of
Christian PE; Williams SP; Burrell L; Castaneda P; Albiani J; Sandella N; Iagaru A; Hoffman JM; de Crespigny A; Bohorquez SS
J Nucl Med Technol; 2020 Mar; 48(1):54-57. PubMed ID: 31604892
[TBL] [Abstract][Full Text] [Related]
4.
Miedema IHC; Wijngaarden JE; Pouw JEE; Zwezerijnen GJC; Sebus HJ; Smit E; de Langen AJ; Bahce I; Thiele A; Vugts DJ; Boellaard R; Huisman MC; Menke-van der Houven van Oordt CW
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067257
[TBL] [Abstract][Full Text] [Related]
5. Preparation of clinical-grade (89) Zr-panitumumab as a positron emission tomography biomarker for evaluating epidermal growth factor receptor-targeted therapy.
Wei L; Shi J; Afari G; Bhattacharyya S
J Labelled Comp Radiopharm; 2014 Jan; 57(1):25-35. PubMed ID: 24448743
[TBL] [Abstract][Full Text] [Related]
6.
Kahts M; Guo H; Kommidi H; Yang Y; Sayman HB; Summers B; Ting R; Zeevaart JR; Sathekge M; Aras O
EJNMMI Radiopharm Chem; 2023 Nov; 8(1):36. PubMed ID: 37930454
[TBL] [Abstract][Full Text] [Related]
7. Investigation of
Alfuraih AA; Alzimami K; Ma AK
Dose Response; 2021; 19(3):15593258211028467. PubMed ID: 34290574
[TBL] [Abstract][Full Text] [Related]
8. First-in-human immunoPET imaging of COVID-19 convalescent patients using dynamic total-body PET and a CD8-targeted minibody.
Omidvari N; Jones T; Price PM; Ferre AL; Lu J; Abdelhafez YG; Sen F; Cohen SH; Schmiedehausen K; Badawi RD; Shacklett BL; Wilson I; Cherry SR
medRxiv; 2023 Mar; ():. PubMed ID: 36993568
[TBL] [Abstract][Full Text] [Related]
9. Imaging Neuroendocrine Prostate Cancer with
Tan KV
Radiol Imaging Cancer; 2023 Jan; 5(1):e239002. PubMed ID: 36661860
[No Abstract] [Full Text] [Related]
10. A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant
Bhatt NB; Pandya DN; Rideout-Danner S; Gage HD; Marini FC; Wadas TJ
Dalton Trans; 2018 Oct; 47(37):13214-13221. PubMed ID: 30178793
[TBL] [Abstract][Full Text] [Related]
11. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
Pandit-Taskar N; O'Donoghue JA; Durack JC; Lyashchenko SK; Cheal SM; Beylergil V; Lefkowitz RA; Carrasquillo JA; Martinez DF; Fung AM; Solomon SB; Gönen M; Heller G; Loda M; Nanus DM; Tagawa ST; Feldman JL; Osborne JR; Lewis JS; Reuter VE; Weber WA; Bander NH; Scher HI; Larson SM; Morris MJ
Clin Cancer Res; 2015 Dec; 21(23):5277-85. PubMed ID: 26175541
[TBL] [Abstract][Full Text] [Related]
12. Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.
Doran MG; Watson PA; Cheal SM; Spratt DE; Wongvipat J; Steckler JM; Carrasquillo JA; Evans MJ; Lewis JS
J Nucl Med; 2014 Dec; 55(12):2045-9. PubMed ID: 25453051
[TBL] [Abstract][Full Text] [Related]
13. Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging.
Zeglis BM; Davis CB; Abdel-Atti D; Carlin SD; Chen A; Aggeler R; Agnew BJ; Lewis JS
Bioconjug Chem; 2014 Dec; 25(12):2123-8. PubMed ID: 25418333
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope.
Ilovich O; Natarajan A; Hori S; Sathirachinda A; Kimura R; Srinivasan A; Gebauer M; Kruip J; Focken I; Lange C; Carrez C; Sassoon I; Blanc V; Sarkar SK; Gambhir SS
Radiology; 2015 Jul; 276(1):191-8. PubMed ID: 25734548
[TBL] [Abstract][Full Text] [Related]
15. Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.
Zeglis BM; Brand C; Abdel-Atti D; Carnazza KE; Cook BE; Carlin S; Reiner T; Lewis JS
Mol Pharm; 2015 Oct; 12(10):3575-87. PubMed ID: 26287993
[TBL] [Abstract][Full Text] [Related]
16. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
[TBL] [Abstract][Full Text] [Related]
17. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo.
Venneti S; Dunphy MP; Zhang H; Pitter KL; Zanzonico P; Campos C; Carlin SD; La Rocca G; Lyashchenko S; Ploessl K; Rohle D; Omuro AM; Cross JR; Brennan CW; Weber WA; Holland EC; Mellinghoff IK; Kung HF; Lewis JS; Thompson CB
Sci Transl Med; 2015 Feb; 7(274):274ra17. PubMed ID: 25673762
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer: Better use of bone scans in prostate cancer.
Larson SM
Nat Rev Urol; 2015 Apr; 12(4):190-1. PubMed ID: 25385459
[No Abstract] [Full Text] [Related]
19. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients.
Baco E; Ukimura O; Rud E; Vlatkovic L; Svindland A; Aron M; Palmer S; Matsugasumi T; Marien A; Bernhard JC; Rewcastle JC; Eggesbø HB; Gill IS
Eur Urol; 2015 Apr; 67(4):787-94. PubMed ID: 25240973
[TBL] [Abstract][Full Text] [Related]
20. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
Ryan CJ; Saylor PJ; Everly JJ; Sartor O
Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
